Illustrated Tiankang Bio's third quarterly report: net profit in the third quarter decreased by 167.45% year-on-year

Tiankang Biology's 2021 third quarter report shows that the company's main revenue was 12.329 billion yuan, up 43.01% year-on-year; net profit attributable to the mother - 192.8592 million yuan, down 113.05% year-on-year; deducted non-net profit - 167.8037 million yuan, down 111.23% year-on-year; of which in the third quarter of 2021, the company's single-quarter main revenue was 4.412 billion yuan, up 12.63% year-on-year. Single-quarter net profit attributable to the mother - 434.256 million yuan, down 167.45% year-on-year; single-quarter non-net profit - 431.6062 million yuan, down 167.6% year-on-year; debt ratio of 54.78%, investment income of 30.9448 million yuan, financial expenses of 149 million yuan, gross profit margin of 12.37%.

There are 1 new top ten circulating shareholders in the current period, Bank of Ningbo Co., Ltd. - Penghua Industrial Upgrading Hybrid Securities Investment Fund holds 5.3827 million shares, accounting for 0.5% of the outstanding shares; a total of 2 shareholders increased their holdings, Hong Kong Securities Clearing Company Limited increased their holdings by 515,969 shares, the shareholder held 0.5% of the outstanding shares, He Sheng increased its holdings of 349,000 shares, the shareholder held 0.45% of the outstanding shares, and a total of 2 shareholders reduced their holdings. Xinjiang Tianda Biological Products Co., Ltd. reduced its holdings by 7.980 million shares, the shareholder held 1.29% of the outstanding shares, Zhu Wentao reduced its holdings by 1.5904 million shares, and the shareholder held 0.98% of the outstanding shares;

For a summary of the financial report data, please see the following figure:

This article is compiled by the Securities Star Data Center based on publicly available data and does not constitute investment opinions or suggestions, if there are any problems in the text, please contact us.